Fig. 1: Killing effects of LXR623 and SR9243 on ccRCC cells. | Cell Death & Disease

Fig. 1: Killing effects of LXR623 and SR9243 on ccRCC cells.

From: Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?

Fig. 1: Killing effects of LXR623 and SR9243 on ccRCC cells.

a CCK8 assays were used to detect the difference in viability of ccRCC cells (786-O and ACHN) after 48, 72 and 96 h of treatment with different doses of SR9243. b CCK8 assays were used to detect the difference in viability of renal cancer cells (786-O and ACHN) after 48, 72 and 96 h of treatment with different doses of LXR623. c CCK8 assays were used to detect cell viability at different times using the same dose use of SR9243 (0.1 µM or 1 µM). d CCK8 assays were used to detect cell viability at different times using the same dose of LXR623 (0.1 µM, 1 µM or 5 µM)

Back to article page